• Aug 2009
    OTAC Cornea and Anterior Segment Disorders Panel, Hoskins Center for Quality Eye Care
    Cornea/External Disease


    A Report by the American Academy of Ophthalmology Ophthalmic Technology Assessment Committee Cornea and Anterior Segment Disorders Panel: W. Barry Lee, MD; Deborah S. Jacobs, MD; David C. Musch, PhD, MPH; Stephen C. Kaufman, MD, PhD; William J. Reinhart, MD; Roni M. Shtein, MD

    Ophthalmology, September 2009, Vol. 116, 1818-1830 © 2009 by the American Academy of Ophthalmology
    Reviewed for currency: 2014

    Objective: To review the published literature on safety and outcomes of Descemet’s stripping endothelial keratoplasty (DSEK) and Descemet’s stripping endothelial automated keratoplasty (DSAEK) for the surgical treatment of endothelial diseases of the cornea.

    Design: Peer-reviewed literature searches were conducted in PubMed and the Cochrane Library with the most recent search in February 2009. The searches yielded 2118 citations in English-language journals. The abstracts of these articles were reviewed and 131 articles were selected for possible clinical relevance, of which 34 were determined to be relevant to the assessment objectives.

    Results: The most common complications from DSEK among reviewed reports included posterior graft dislocations (mean, 14%; range, 0%-82%), followed by endothelial graft rejection (mean, 10%; range, 0%-45%), primary graft failure (mean, 5%; range, 0%-29%), and iatrogenic glaucoma (mean, 3%; range, 0%-15%). Average endothelial cell loss as measured by specular microscopy ranged from 25% to 54% with an average cell loss of 37% at 6 months and from 24% to 61%, with an average cell loss of 42% at 12 months. The average best-corrected Snellen visual acuity (mean, 9 months; range, 3-21 months) ranged from 20/34 to 20/66. A review of postoperative refractive results found induced hyperopia ranging from 0.7 to 1.5 diopters (D; mean, 1.1 D) with minimal induced astigmatism ranging from -0.4 to 0.6 D and a mean refractive shift of 0.11 D. A review of graft survival found that clear grafts at 1 year ranged from 55% to 100% (mean, 94%).

    Conclusions: The evidence reviewed is supportive of DSEK being a safe and effective treatment for endothelial diseases of the cornea. In terms of surgical risks, complication rates, graft survival (clarity), visual acuity, and endothelial cell loss, DSEK appears similar to penetrating keratoplasty (PK). It seems to be superior to PK in terms of earlier visual recovery, refractive stability, postoperative refractive outcomes, wound and suture-related complications, and intraoperative and late suprachoroidal hemorrhage risk. The most common complications of DSEK do not appear to be detrimental to the ultimate vision recovery in most cases. Long-term endothelial cell survival and the risk of late endothelial rejection are beyond the scope of this assessment.